files/journal/2022-09-03_18-51-40-000000_599.png

Research Journal of Medical Sciences

ISSN: Online 1993-6095
ISSN: Print 1815-9346

References

  1. WHO., 2017. Global Tuberculosis Report 2017. World Health Organization, Geneva, ISBN-13: 9789241565516, Pages: 249.
  2. Kim, H.Y., K.S. Song, J.M. Goo, J.S. Lee, K.S. Lee and T.H. Lim, 2001. Thoracic sequelae and complications of tuberculosis. Radiographics, 21: 839-858.
  3. Rajasekaran, S., V. Vallinayagi and D. Jeyaganesh, 1999. Unilateral lung destruction: A computed tomographic evaluation. Indian J. Tuberculosis, 46: 183-188.
  4. Pasipanodya, J.G., T.L. Miller, M. Vecino, G. Munguia and R. Garmon et al., 2007. Pulmonary impairment after tuberculosis. Chest, 131: 1817-1824.
  5. Vecino, M., J.G. Pasipanodya, P. Slocum, S. Bae and G. Munguia et al., 2011. Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis. J. Infec. Public Health, 4: 244-252.
  6. Pasipanodya, J.G., S.J. McNabb, P. Hilsenrath, S. Bae and K. Lykens et al., 2010. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health, Vol. 10. 10.1186/1471-2458-10-259.
  7. Plit, M., R. Anderson, C.V. Rensburg, L. Page-Shipp, J. Blott, J. Fresen and C. Feldman, 1998. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur. Respir. J., 12: 351-356.
  8. Pasipanodya, J.G., E. Vecino, T.L. Miller, G. Munguia and G. Drewyer et al., 2012. Non-hispanic whites have higher risk for pulmonary impairment from pulmonary tuberculosis. BMC Public Health, Vol. 12. 10.1186/1471-2458-12-119.
  9. de Vallière, S. and R.D. Barker, 2004. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis., 8: 767-771.
  10. Menezes, A.M.B., P.C. Hallal, R. Perez-Padilla, J.R.B. Jardim and A. Muiño et al., 2007. Tuberculosis and airflow obstruction: Evidence from the PLATINO study in Latin America. Eur. Respir. J., 30: 1180-1185.
  11. Chung, K.P., J.Y. Chen, C.H. Lee, H.D. Wu and J.Y. Wang et al., 2011. Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics, 66: 549-556.
  12. Naso, F.C.D., J.S. Pereira, S.J. Schuh and G. Unis, 2011. Avaliação funcional em pacientes com sequela pulmonar de tuberculose. Rev. Portuguesa Pneumologia, 17: 216-221.
  13. Kim, H.Y., K.S. Song, J.M. Goo, J.S. Lee, K.S. Lee and T.H. Lim, 2001. Thoracic sequelae and complications of tuberculosis. Radiographics, 21: 839-860.
  14. Elkington, P.T.G., 2006. Matrix metalloproteinases in destructive pulmonary pathology. Thorax, 61: 259-266.
  15. Gothi, D., D.V. Shah and J.M. Joshi, 2007. Clinical profile of diseases causing chronic airflow limitation in a tertiary care centre in India. J. Assoc. Physic. India, 55: 551-555.
  16. Maguire, G.P., N.M. Anstey, M. Ardian, G. Waramori, E. Tjitra et al., 2009. Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int. J. Tuberc. Lung Dis., 13: 1500-1506.
  17. Báez-Saldaña, R., Y. López-Arteaga, A. Bizarrón-Muro, E. Ferreira-Guerrero and L. Ferreyra-Reyes et al., 2013. A novel scoring system to measure radiographic abnormalities and related spirometric values in cured pulmonary tuberculosis. PLoS ONE, Vol. 8. 10.1371/journal.pone.0078926.
  18. Greenaway, C., D. Menzies, A. Fanning, R. Grewal and L. Yuan et al., 2001. Delay in diagnosis among hospitalized patients with active tuberculosis: Predictors and outcomes. Am. J. Respir. Crit. Care Med., 165: 927-933.
  19. Rodger, A., S. Jaffar, S. Paynter, A. Hayward, J. Carless and H. Maguire, 2003. Delay in the diagnosis of pulmonary tuberculosis, London, 1998-2000: Analysis of surveillance data. BMJ, 326: 909-910.
  20. Willcox, P.A. and A.D. Ferguson, 1989. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir. Med., 83: 195-198.
  21. Miguel-Reyes, J.L., L. Gochicoa-Rangel, R. Pérez-Padilla and L. Torre-Bouscoulet, 2015. Functional respiratory assessment in interstitial lung disease. Rev. Invest. Clin., 67: 5-14.